Search Results

neuropathy.” Omitting bolus fluorouracil, reducing doses, eliminating drugs that cause excessive toxicity, and using chemotherapy holidays have been found to increase the tolerability of this regimen. Another frequently used regimen, nab-paclitaxel

chemotherapy and pembrolizumab regimen in this setting in August 2018. Another key frontline immunotherapy option for patients with non-SCC NSCLC (especially those who are pemetrexed-ineligible) is the 4-drug regimen of atezolizumab/carboplatin/paclitaxel

became available for the treatment of NSCLC. The large phase III ECOG 1594 trial randomized 1155 patients with advanced NSCLC with a performance status (PS) of 0 to 2 to a reference regimen of cisplatin and paclitaxel versus 3 other platinum

radiographic evidence of acute pancreatitis ( Figure 1 ). Figure 1. Study flow diagram. Abbreviations: FOLFIRINOX, 5-fluorouracil/leucovorin/oxaliplatin/irinotecan; Gem/Nab-paclitaxel, gemcitabine + nanoparticle albumin–bound paclitaxel; PDAC

This study analyzed preexisting, deidentified data, and was therefore deemed exempt from Institutional Review Board approval. Study Population We identified patients who initiated AC, TAC (paclitaxel or docetaxel with doxorubicin and

Einhorn LH . Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): A trial of the Eastern Cooperative Oncology Group . J Clin Oncol 2002 ; 20 : 1859 – 1863 . 18 Hartmann JT Schleucher N Metzner B . Phase I

. Moore DH Blessing JA McQuellon RP . Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study . J Clin Oncol 2004 ; 22 : 3113 – 3119

, patients received an average of 5 chemotherapy treatments (range, 2–6), with an average relative dose intensity of 91.8% for carboplatin and 86.7% for paclitaxel. During the STRENGTH period, patients received an average of 6 (range, 5–8) chemotherapy

only due to smaller sample sizes. The RR of a dose reduction or delay for doxorubicin, docetaxel, and paclitaxel was assessed independently. Cyclophosphamide was not assessed because it was exclusively administered concurrent to doxorubicin or docetaxel

paclitaxel (Taxol, Bristol-Myers Squibb Company) as an appropriate therapeutic option for metastatic breast cancer with the evidence designation 2A meaning that it is based on lower level evidence and uniform agreement of the panel as to its appropriateness